Related references
Note: Only part of the references are listed.
Article
Infectious Diseases
Shengli Xia et al.
Summary: The inactivated SARS-CoV-2 vaccine, BBIBP-CorV, demonstrated safety and immunogenicity in two age groups. Humoral responses against SARS-CoV-2 were induced in all vaccine recipients by day 42. A two-dose immunisation with 4 mu g vaccine on days 0 and 21 or days 0 and 28 achieved higher neutralising antibody titres compared to other dosing schedules.
LANCET INFECTIOUS DISEASES
(2021)
Letter
Infectious Diseases
Wey Wen Lim et al.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Volunteers who received the Moderna or Pfizer-BioNTech vaccine showed high levels of antibodies and memory B cell responses against SARS-CoV-2, with activity similar to individuals who had recovered from natural infection. However, their efficacy against specific SARS-CoV-2 variants was reduced, indicating a potential need for periodic updates to mRNA vaccines to maintain clinical efficacy.
Article
Biochemistry & Molecular Biology
Rita E. Chen et al.
Summary: The study analyzed antibody neutralization activity against a panel of authentic isolates and chimeric SARS-CoV-2 variants, showing significantly reduced neutralizing activity against the B.1.351 variant first identified in South Africa. Antibodies targeting the receptor-binding domain and N-terminal domain, monoclonal antibodies, convalescent sera, and mRNA vaccine-induced immune sera exhibited decreased inhibitory activity against viruses with an E484K spike mutation, suggesting a need for updated monoclonal antibodies or vaccine adjustments to prevent loss of protection against emerging variants.
Letter
Medicine, General & Internal
Guo-Lin Wang et al.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Letter
Cell Biology
Xingdong Zhou et al.
Article
Biochemistry & Molecular Biology
Chang Liu et al.
Summary: Recent study examined the neutralizing ability of monoclonal antibodies, convalescent and vaccine sera against the Indian variants B.1.617.1 and B.1.617.2, showing that the neutralization of these variants is reduced compared to the ancestral strains, without widespread antibody escape as seen in other variants like B.1.351.
Review
Microbiology
Kanta Subbarao
Summary: The development of effective SARS-CoV-2 vaccines is facing challenges in preventing asymptomatic and mild infections, potential updates required due to the emergence of variants with mutations, and concerns about the longevity of vaccine-induced immunity. Coordination in global surveillance, updating vaccines, and potential re-vaccination may be necessary to address these challenges.
CELL HOST & MICROBE
(2021)
Article
Immunology
Ruoke Wang et al.
Summary: Research shows that the South African B.1.351 variant exhibits the highest resistance to current monoclonal antibodies and convalescent plasma from COVID-19-infected individuals, and the molecular basis for this resistance and potential antibody escape has been identified.
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The SARS-CoV-2 B.1.617 Delta variant, first identified in India in 2020, has become dominant in some regions and is spreading to many countries. This variant shows resistance to certain monoclonal antibodies and antibodies in convalescent sera, as well as reduced neutralization by some COVID-19 vaccines. Administration of two doses of the vaccine is needed for a neutralizing response against the Delta variant.
Article
Multidisciplinary Sciences
Qi Zhang et al.
Summary: The study identifies potent neutralizing antibodies against SARS-CoV-2 with shared genetic features, termed as public antibodies. While one representative antibody demonstrates high protective efficacy in experiments, virus escape analysis reveals challenges faced by these public antibodies.
NATURE COMMUNICATIONS
(2021)
Review
Immunology
Lianpan Dai et al.
Summary: The urgent need for vaccines to control the COVID-19 pandemic has led to the rapid development of multiple vaccine candidates, with some showing positive results in late-stage clinical trials. This article discusses the viral elements used in these candidates, the reasons why they are good targets for the immune system, and their implications for protective immunity. Dai and Gao highlight the importance of selecting the right viral targets in vaccine development to ensure an effective immune response and the overall safety and efficacy of the vaccine.
NATURE REVIEWS IMMUNOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Hui Wang et al.
Article
Multidisciplinary Sciences
Davide F. Robbiani et al.
Article
Multidisciplinary Sciences
Christopher O. Barnes et al.
